The shift in cytokine profile during human immunodeficiency virus (HIV) disease progression is influenced by dehydroepiandrosterone sulfate (DHEAS) level. Radioimmunoassay was used to measure plasma DHEAS for 30 treatment-naïve HIV-infected and 30 uninfected individuals. There was a significant negative correlation of viral load with DHEAS level (P < 0.05). Further studies of the use of DHEAS levels for monitoring HIV patients economically are warranted.Progression of human immunodeficiency virus (HIV) infection is marked by severe immunosuppression, especially during the advanced stages, as a result of selective depletion of CD4 lymphocytes. Primary HIV infection is characterized by detectable humoral and cellular immune responses. During progression to AIDS, there is a shift from a TH1 to a TH2 cytokine profile (3). It has been suggested that this shift in cytokine profile is in part influenced by the increase in the production of cortisol and the reduction of dehydroepiandrosterone (DHEA) (4). The level of change in the cortisol/DHEA ratio could be predictive of progression to AIDS in HIV-infected individuals (2). Studies have shown significant relationships among the CD4 cell count, the development of cachexia, and levels of serum cortisol and DHEA (1). The present study was done on an Indian population to investigate the relationship between the decline in levels of dehydroepiandrosterone sulfate (DHEAS) and HIV infection progression as well as HIV-1 viral load.Blood samples were collected from 30 treatment-naïve HIVinfected individuals (24 men and 6 women; median age, 33 years; range, 22 to 55 years) and 30 normal healthy age-and sex-matched individuals (24 men and 6 women; median age, 35 years; range, 22 to 58) after obtaining informed consent. Blood samples were drawn between 8 and 10 a.m. on the days of sampling. None of the HIV-infected or the normal healthy individuals had Cushing's syndrome or Addison's disease. The HIV-1 viral load and CD4 ϩ and CD8 ϩ T-cell estimations were done for all the HIV-infected individuals using standard methods.A commercially available radioimmunoassay (Diagnostic Products Corporation) was used to measure DHEAS concentration. The assay was carried out as per the manufacturer's instructions. Briefly, in polypropylene tubes coated with antibodies to DHEAS, ligands in the patient samples compete with 125 I-labeled DHEAS. After incubation and separation of the bound from the free form, the tubes were read in a gamma counter (Wallac; GMI, Inc., Minnesota). The counts were inversely related to the amount of DHEAS in the sample. A calibration curve was then used to quantify the DHEAS in the sample. Viral loads were determined using Amplicor HIV-1 Monitor test v1.5. The CD4 ϩ T-cell counts were measured by flow cytometry for 14 individuals (Becton Dickinson, San Jose, CA) and by the Capcellia assay (Bio-Rad, Paris, France) for the remaining 16 samples. For the correlation analysis between DHEAS and CD4 cell counts, only those 14 patients whose CD4 cell counts were measured by flo...